Open AccessPositioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
Author(s) -
Pericay Carles,
Rivera Fernando,
GomezMartin Carlos,
Nuñez Inmaculada,
Cassinello Alejo,
Imedio Esteban Rodrigo
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.941
Subject(s) - ramucirumab , medicine , paclitaxel , gastroesophageal junction , cancer , adenocarcinoma , oncology , clinical trial , chemotherapy , incidence (geometry) , disease , first line , second line treatment , intensive care medicine , physics , optics
Tumors of the upper gastrointestinal tract are increasing in incidence; yet, approaches to the treatment of advanced gastric and/or gastroesophageal junction cancer vary widely, with no internationally agreed first‐line regimens. Recent clinical trials have shown that second‐line treatment is now possible for selected patients with advanced disease, and current data suggest that the combination of ramucirumab plus paclitaxel may become a standard of care in the second‐line setting for metastatic gastric cancer. Several prognostic factors have been identified for overall survival in the second‐line setting; this emphasizes the need for careful sequencing of all treatments to ensure that individual patients receive optimum care. This article reviews published data on the treatment of advanced gastric cancer, with a particular emphasis on second‐line chemotherapy, and suggests treatment sequences based on current understanding.